Pembrolizumab + Lenvatinib for Skin and Kidney Cancers with Brain Metastases
Trial Summary
The trial protocol does not specify if you need to stop taking your current medications. However, it mentions that participants should not have received anti-cancer therapy within 14 days before starting the trial and should not be on high doses of steroids or immunosuppressive therapy. It's best to discuss your specific medications with the trial team.
Research shows that the combination of pembrolizumab and lenvatinib has been effective in treating advanced gastric cancer, renal cell carcinoma, and urothelial carcinoma, suggesting potential benefits for other cancers as well. This combination has shown antitumor activity and is considered a standard treatment for certain types of kidney cancer.
12345The combination of pembrolizumab and lenvatinib has been studied in various cancers and has shown a manageable safety profile, meaning that while there are side effects, they can generally be managed with appropriate care.
24678The combination of pembrolizumab and lenvatinib is unique because it pairs an immune checkpoint inhibitor (pembrolizumab) with a multikinase inhibitor (lenvatinib), which together enhance the body's immune response against tumors. This combination has shown promise in treating various cancers, including renal cell carcinoma, by improving anti-tumor activity compared to using either drug alone.
12356Eligibility Criteria
Adults with melanoma or renal cell carcinoma (RCC) and untreated brain metastases who've had at least two doses of anti-PD-1/PD-L1 drugs. They must not be pregnant, agree to contraception, have a life expectancy over 3 months, stable blood pressure, good organ function, and an ECOG status of 0-1. Exclusions include symptomatic brain metastases, recent cancer treatments or vaccines, serious infections or bleeding risks.Inclusion Criteria
Exclusion Criteria
Participant Groups
- Differentiated Thyroid Cancer
- Renal Cell Carcinoma
- Hepatocellular Carcinoma
- Endometrial Cancer
- Thyroid Cancer
- Renal Cell Carcinoma
- Hepatocellular Carcinoma
- Endometrial Cancer
- Renal Cell Carcinoma